For research use only. Not for therapeutic Use.
Eprodisate is a new compound designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues[1].
Eprodisate slow the progression of AA amyloidosis-related renal disease and has possible applicability to other types of amyloidosis[2].
| Catalog Number | I018600 |
| CAS Number | 21668-77-9 |
| Synonyms | propane-1,3-disulfonic acid |
| Molecular Formula | C3H8O6S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C3H8O6S2/c4-10(5,6)2-1-3-11(7,8)9/h1-3H2,(H,4,5,6)(H,7,8,9) |
| InChIKey | MGNVWUDMMXZUDI-UHFFFAOYSA-N |
| SMILES | C(CS(=O)(=O)O)CS(=O)(=O)O |
| Reference | [1]. Dember LM, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2349-60. [2]. Manenti L, et al. Eprodisate in amyloid A amyloidosis: a novel therapeutic approach? Expert Opin Pharmacother. 2008 Aug;9(12):2175-80. |
